Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China
For Patients with recurrent or newly diagnosed advanced head and neck squamous cell carcinoma, TMC-I is cost-effective at a WTP thresholds of ¥134,037/QALY and is not cost-effective when the WTP thresholds was ¥44,679/QALY compared with TMC.
Authors
- Fenghao Shi
- Yingdan Cao (ORCID: https://orcid.org/0009-0006-7414-4674)
- Fang Yu (ORCID: https://orcid.org/0000-0002-7495-6449)
- Sheng Han (ORCID: https://orcid.org/0000-0001-5975-3574)
- Xiaoxia Wei
Institutions
- Fujian Medical University (CN)
- Peking University (CN)
- Peking University International Hospital (CN)
- Fujian Provincial Hospital (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.3389/fonc.2025.1542792
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00